Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025
Rhea-AI Summary
Teknova (Nasdaq: TKNO), a producer of critical reagents for therapies, vaccines, and molecular diagnostics, has scheduled its Q2 2025 financial results announcement for August 7, 2025, after market close.
The company will host a conference call and webcast at 5 p.m. Eastern Time on the same day. Investors can access the webcast through Teknova's Investor Relations website, and participants wanting to join the call need to register to receive dial-in information. A replay will be available approximately two hours after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, TKNO gained 0.19%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market.
Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in molecular diagnostics, synthetic biology, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.
Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
This press release was published by a CLEAR® Verified individual.
FAQ
When will Teknova (TKNO) report Q2 2025 earnings?
What time is Teknova's Q2 2025 earnings call?
How can investors access Teknova's Q2 2025 earnings call?
Will there be a replay of Teknova's Q2 2025 earnings call?
